Affiliations: [a] Clinic for Urology and Paediatric Urology, University Hospital of Bonn, 53127 Bonn, Germany | [b] Institute of Pathology, University Hospital of Bonn, 53127 Bonn, Germany
Correspondence:
[*]
Corresponding author: Isabella Syring, Clinic for Urology and Paediatric Urology, University Hospital of Bonn, Sigmund-Freud-Straße 25, 53127 Bonn, Germany. Tel.: +49 228 287 14184; Fax: +49 228 287 19150; E-mail: [email protected].
Abstract: BACKGROUND/OBJECTIVE: MED15 is a part of the multiprotein Mediator complex which is involved in the transcription of polymerase (Pol) II-dependent genes. Several studies in this field have reported altered expressions of distinct subunits in human malignancy. However, the role of MED15 in renal cell carcinoma (RCC) has not be investigated yet. METHODS: First, we performed an RNA expression and survival analysis of MED15 in RCC by using the database cBioPortal. To confirm these data on the protein level, we executed immunohistochemical (IHC) staining against MED15 on a tissue microarray containing 184 samples of the most common subtypes of the tumour at the various stages. Further, we performed functional analysis including proliferation, migration, and invasion assays on the RCC cell lines A-498 and ACHN following the siRNA-mediated MED15 knockdown. RESULTS: On the mRNA level, higher expression of MED15 was associated with worse patient survival rates. IHC staining validated this tendency, unfortunately the results were not significant. However, supporting this tendency, in vitro-assays showed a significant decrease in proliferation, migration, and invasion after knockdown of MED15. CONCLUSION: The research concludes that MED15 does seem to play a tumour promoting role in the progression and metastatic spread of renal cell carcinoma.
